

Histovathology

Small cell carcinoma of the endometrium has features resembling small cell carcinoma of the lung. The growth pattern is usually diffuse with extensive necrosis. The cells are small or of intermediate size with hyperchromatic nuclei, numerous mitotic figures and scanty cytoplasm. Immunohistochemical evidence of neuroendocrine differentiation is demonstrated in most tumors (neuron-specific enolase, chromogranin, synaptophysin, leu-7). Some tumors show an admixture with ordinary adenocarcinoma or squamous cell differentiation.

Prognosis

In contrast to the common types of endometrial carcinoma, most patients with small cell carcinoma present with advanced stage and die of widespread disease within a year. In the Norwegian series, the 5-year survival was 64%. This is probably due to a better stage distribution compared to other published series with this disease. The mean age is about 58 years.

Differential diagnosis

The differential diagnosis is with malignant lymphoma, leukemia, stromal sarcoma, embryonal rhabdomyosarcoma, primitive neuroectodermal tumors and malignant mixed müllerian tumor.

References

1. Abeler vM, Kierstad KB. *Clear cell carcinoma of the endometrium: A histopathological and clinical study of 97 cases.* Gynecol Oncol 1991; 40: 207-217.
2. Abeler vM, Kierstad KB. *Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases.* Gynecol Oncol 1990; 39: 266-271.
3. Abeler VM, Kierstad KE, Nesland JM. *Undifferentiated carcinoma of the endometrium. A histopathological study of 31 cases.* Cancer 1991; 68.
4. Abeler VM, Vergote B, Kjerstad KE et al. *Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern.* Cancer 1996; 76:1740-1747.
5. Ambros AA, Sherman ME, Zaho CM et al. *Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation.* Hum Pathol 1995; 26: 1260-1267.
6. Hendrickson M, Ross J, Bitel P et al. *Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma.* Am J Surg Pathol 1962; 6: 93-108.
7. Huntsman OG, Clement PB, Gilka CR et al. *Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases.* Am J Surg Pathol 1994; 18: 364-375.
8. Scully RE, Barium JF. *Mesonephroma of the ovary. Tumor of the Müllerian nature related to the endometrioid carcinoma.* Cancer 1967; 20: 1405-1410.
9. V Hoeven KH, Hudock JA, Woodruff JM et al. *Small cell neuroendocrine carcinoma of the endometrium.* Int J Gynecol Pathol 1995; 14: 21-29.

Mesenchymal tumors of the uterus

T.R Rollason

Birmingham, UK.

This paper confines itself to discussing recent changes in opinion or understanding of uterine pure mesenchymal tumors.

Smooth muscle tumors

Mitotically active leiomyomas

It has become clearer in the past 5 years what the relative value of mitotic counts in uterine smooth muscle tumors (SMTs) is. Previous

recommendations regarding mitotic counts and outcome are now known to have been too dogmatic. Leiomyomata without significant cytological atypia (none or only mild atypia) may have mitotic counts up to 20 per 10 high power field (HPF) and still pursue a benign course. Such tumors tend to occur in reproductive life and to be seen especially in the secretory phase of the cycle. Mitotically active leiomyomata should not show abnormal mitoses or coagulative necrosis. Cytologically bland tumors with more than 20 mitoses per 10 HPF are not yet sufficiently well understood for definite comment.

Leiomyomas with bizarre nuclei

When leiomyomas with bizarre nuclei show focal atypia without coagulative necrosis or abnormal mitoses, they may behave as benign tumors even with mitotic counts above 10 per HPF. In the series of Bell *et al.*, diffuse atypia and a mitotic count above 10 per 10 HPF was associated with malignant behavior. A more recent paper suggests that half of "bizarre leiomyomas" show diffuse atypia and confirms that maximum mitotic rates of up to 7 per 10 HPF may be seen without malignant behavior.

Epithelioid smooth muscle tumors

Well-defined margins, a clear cell pattern, hyalinization and the absence of necrosis are good prognostic features in epithelioid SMTs. Mitoses may be low, however, even in frank epithelioid leiomyosarcomas, with some having mitotic rates as low as 3-4 per 10 HPF. Most, but not all, malignant examples show pleomorphism, necrosis and hypercellularity and caution is required in the diagnosis of these tumors.

Myxoid smooth muscle tumors

Myxoid SMTs are uncommon but increased mitotic rates and pleomorphism etc. may be absent even in highly aggressive examples. The presence of an infiltrative margin and a size greater than 4.0 cm are indications of malignancy and all myxoid SMTs must be treated with caution. They should be differentiated from leiomyomas with hydropic degeneration and "perinodular hydropic leiomyomas."

Cellular smooth muscle tumors

Cellularity *per se* is not a worrying feature in SMTs unless accompanied by pleomorphism etc.. Cellular SMTs may, however, be very difficult to distinguish from stromal tumors. Unlike stromal tumors they tend to merge with the myometrium at their periphery and have large, thick walled blood vessels in contrast to the small arterioles typical of stromal tumors. Cellular leiomyomas may also show cleft-like spaces. Immunohistochemistry is of limited value.

Hemorrhagic cellular (aboolectic) leiomyomas

Pregnancy, progesterone therapy and gonadotropin-releasing hormone analog therapy may all produce worrying changes in benign SMTs, including pleomorphism, infarction, increased mitoses and hemorrhage. The keys to the correct interpretation of these benign, but worrying, changes are the clinical history, lack of coagulative necrosis, well-defined tumor margins and occurrence of the changes in several tumors.

Stromal tumors

The classical differentiation of stromal tumors into stromal nodules, low-grade stromal sarcomas and high-grade stromal sarcomas has

been challenged in recent years, with many arguing that most cases of high-grade stromal sarcoma are simply undifferentiated sarcomas. The differentiation of stromal nodule from low-grade stromal sarcoma depends on demonstrating an infiltrative margin and/or vessel invasion in the latter. Cases of low-grade stromal sarcoma confined to the uterus at original presentation appear to have a very low risk of recurrence.

Recently the spectrum of differentiation patterns in low-grade stromal sarcoma has been extended. As well as sex-cord-like areas, rhabdoid and retiform differentiation have recently been described. True glands and tubules are well described and it seems likely that most examples of aggressive endometriosis represent low-grade stromal sarcoma with extensive endometrioid glandular differentiation.

It is common for stromal tumors to show areas of smooth muscle differentiation. Those where more than 30% of the tumor was made up of the lesser element (sometimes called stromomyomas) have recently been the subject of a study which suggests that they should be reported as endometrial stromal nodules or low-grade stromal sarcomas with smooth muscle differentiation, as the one tumor of seven with follow-up that recurred, did so as a pure low-grade stromal sarcoma.

Sarcoma botryoides of the cervix of young women

Several recent papers have confirmed Daya and Scully's observation that sarcoma botryoides is usually cured by local therapy (though in the literature such local removal has usually been combined with chemotherapy). It is a tumor occurring mainly in teen-

agers (mean age 18). Eighty percent of cases appear free of disease at 5 years though it is not possible on histological appearances to predict those cases that will follow an aggressive course.

References

- Bell S, Kempson RL, Hendrickson MR. *Problematic uterine smooth muscle neoplasms: A clinicopathological study of 213 cases*. Am J Surg Pathol 1994; 18: 535-558.
- Chang KL, Crsbtree GS, Lim-Tan S et al. *Primary uterine endometrial stromal neoplasms*. Am J Surg Pathol 1990; 14: 415-438.
- Clement PB, Young RH, Scully RE. *Diffuse, perinodular, and other patterns of hydropic degeneration within and adjacent to uterine leiomyomas. Problems in differential diagnosis*. Am J Surg Pathol 1992; 16: 26-32.
- Daya DA, Scully RE. *Sarcoma botryoides of the uterine cervix in young women: A clinicopathological study of 13 cases*. Gynecol Oncol 1988; 29: 290-304.
- Downes KA, Hart WR. *Bizarre leiomyomas of the uterus: A comprehensive pathologic study of 24 cases with long term follow-up*. Am J Surg Pathol 1997; 21: 261-270.
- King ME, Dickersin GR, Scully RE. *Myxoid leiomyosarcoma of the uterus. A report of 6 cases*. Am J Surg Pathol 1982; 6: 589-598.
- Norris HJ, Hillard GD, Irey NS. *Haemorrhagic cellular leiomyomas (apoplectic leiomyoma) of the uterus associated with pregnancy and oral contraception*. Int J Gynecol Pathol 1998; 7: 212-224.
- Oliva E, Young RH, Clement PB et al. *Cellular benign mesenchymal tumours of the uterus*. Am J Surg Pathol 1995; 19: 757-768.
- Oliva E, Clement PB, Young RH et al. *Mixed endometrial stromal and smooth muscle tumors of the uterus: a clinicopathologic study of 15 cases*. Am J Surg Pathol 1998; 8: 997-1005.
- Prayson RA, Golblum JR, Hart WR. *Epithelioid smooth muscle tumours of the uterus. A clinicopathologic study of 18 patients*. Am J Surg Pathol 1997; 21: 383-391.